



**COVERAGE DETERMINATION REQUEST FORM**



EOC ID:  
Non Formulary Exception (NFE) Request-8A Medicare

Phone: 866-250-2005 Fax back to: 877-503-7231

Elixir manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

<b>Patient Name:</b>	<b>Prescriber Name:</b>	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

**\*Please note that Elixir will process the request as written, including drug name, with no substitution.**

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

**Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.**

<p>Q1. Is this request for initial or continuing therapy?</p> <p><input type="checkbox"/> Initial therapy <input type="checkbox"/> Continuing therapy</p>
<p>Q2. Please indicate the patient's diagnosis for the requested medication:</p>
<p>Q3. Where does the patient reside?</p> <p><input type="checkbox"/> Long Term Care/Intermediate Care Facility  <input type="checkbox"/> Home residence  <input type="checkbox"/> None of the above</p>
<p>Q4. Please list all medications that were tried and failed for the submitted diagnosis and REASON FOR THERAPY FAILURE (i.e. ineffective, intolerance, adverse reaction, etc.).</p>
<p>Q5. If formulary alternatives not listed in previous question are contraindicated or not appropriate, provide reason(s) why.</p>
<p>Q6. FOR B vs D DME Infusion or Inhalation medications, please select all that apply to this patient:</p>



**COVERAGE DETERMINATION REQUEST FORM**

EOC ID:

Non Formulary Exception (NFE) Request-8A Medicare



Phone: 866-250-2005

Fax back to: 877-503-7231

Elixir manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

<b>Patient Name:</b>	<b>Prescriber Name:</b>
----------------------	-------------------------

- The medication is being given via an infusion pump
- Medicare paid for the infusion pump
- The medication is being given via IV push or infusion drip (gravity method)
- The medication is not being administered via the IV route, it is being used SQ or IM
- The medication will be administered via a nebulizer (for oral inhalation medications)
- Not Applicable -The medication is not being given via injection or nebulizer

Q7. FOR B vs D Incident to Physicians Service review, please select all that apply to this patient:

- The medication will be administered in a physician's office
- The physician's office will furnish the medication from their stock
- The patient will get the medication from a pharmacy
- None of the above

Q8. FOR B vs D ESRD review, please select all that apply to this patient and the intended use of the requested medication (please select all that apply):

- The patient is on dialysis
- To prevent or treat bone disease SECONDARY TO DIALYSIS (i.e. hyperparathyroidism)
- To treat carnitine deficiency secondary to chronic kidney disease AND the medication will be administered at the dialysis facility
- To treat a dialysis access site infection
- To treat the dialysis access site
- To treat anemia due to chronic kidney disease
- To treat dialysis related access management (e.g. to dissolve possible blood clots around an infusion line or graft)
- Not Applicable - the medication is not being used for ESRD

\_\_\_\_\_  
Prescriber Signature

\_\_\_\_\_  
Date

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document